AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for
Parkinson's Disease with AMT's Proprietary Gene Therapy Platform
(18/09/08 09:12 CET)

Amsterdam, The Netherlands - September 18, 2008 - Amsterdam Molecular
Therapeutics (Euronext: AMT), a leader in the field of human gene
therapy, today announced that it obtained a license from Amgen to use
their GDNF gene for the development of a gene therapy treatment for
Parkinson's disease. The combination of this gene with AMT's
proprietary adeno-associated virus (AAV) gene therapy platform could
potentially allow the development of an effective, long-term treatment
for this progressive and crippling disease.


(read entire article)

HOORAY!!!!